Growing evidence has demonstrated the critical role of PI3K/mTOR pathway in the maintenance of CSCs, and that targeting PI3K/mTOR signaling may be beneficial in cancer treatment by eliminating CSCs [12, 13, 46]. This evidence concerns the gene PIK3CD and cancer.